1.72
price down icon6.01%   -0.11
after-market Dopo l'orario di chiusura: 1.72
loading
Precedente Chiudi:
$1.83
Aprire:
$1.8
Volume 24 ore:
1.27M
Relative Volume:
0.59
Capitalizzazione di mercato:
$143.98M
Reddito:
$32.31M
Utile/perdita netta:
$-237.09M
Rapporto P/E:
-0.5972
EPS:
-2.88
Flusso di cassa netto:
$-219.11M
1 W Prestazione:
+10.97%
1M Prestazione:
+10.97%
6M Prestazione:
-23.21%
1 anno Prestazione:
-66.73%
Intervallo 1D:
Value
$1.70
$1.81
Intervallo di 1 settimana:
Value
$1.5646
$1.9499
Portata 52W:
Value
$0.9101
$6.22

Editas Medicine Inc Stock (EDIT) Company Profile

Name
Nome
Editas Medicine Inc
Name
Telefono
617-401-9000
Name
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Name
Dipendente
226
Name
Cinguettio
@editasmed
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
EDIT's Discussions on Twitter

Confronta EDIT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
EDIT
Editas Medicine Inc
1.72 129.75M 32.31M -237.09M -219.11M -2.88
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-28 Iniziato H.C. Wainwright Buy
2024-12-16 Downgrade JP Morgan Neutral → Underweight
2024-12-13 Downgrade Chardan Capital Markets Buy → Neutral
2024-12-13 Downgrade Stifel Buy → Hold
2024-12-13 Downgrade Truist Buy → Hold
2024-12-11 Downgrade Wells Fargo Overweight → Equal Weight
2024-11-25 Downgrade BofA Securities Buy → Underperform
2024-11-06 Aggiornamento Evercore ISI In-line → Outperform
2024-11-04 Downgrade Raymond James Outperform → Mkt Perform
2024-08-08 Aggiornamento BofA Securities Neutral → Buy
2024-05-09 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2023-10-24 Aggiornamento Citigroup Neutral → Buy
2023-10-18 Aggiornamento JP Morgan Underweight → Neutral
2023-10-17 Downgrade Cantor Fitzgerald Overweight → Neutral
2023-09-29 Aggiornamento Stifel Hold → Buy
2023-06-12 Aggiornamento Raymond James Mkt Perform → Outperform
2023-02-01 Iniziato Cantor Fitzgerald Overweight
2022-12-13 Iniziato Citigroup Neutral
2022-12-06 Ripresa Credit Suisse Neutral
2022-11-18 Downgrade Credit Suisse Outperform → Neutral
2022-11-18 Downgrade Oppenheimer Outperform → Perform
2022-09-29 Iniziato BofA Securities Neutral
2021-10-19 Iniziato SVB Leerink Mkt Perform
2021-09-24 Iniziato Stifel Hold
2021-09-10 Aggiornamento Oppenheimer Perform → Outperform
2021-08-09 Aggiornamento Truist Hold → Buy
2021-08-05 Aggiornamento Evercore ISI Underperform → Outperform
2021-06-04 Ripresa Robert W. Baird Outperform
2021-05-04 Iniziato RBC Capital Mkts Sector Perform
2021-04-16 Iniziato Goldman Sell
2021-03-22 Iniziato Credit Suisse Outperform
2021-03-01 Downgrade Barclays Overweight → Equal Weight
2021-02-26 Downgrade Truist Buy → Hold
2021-01-19 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-01-07 Downgrade Raymond James Outperform → Mkt Perform
2020-12-10 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-11-03 Iniziato Robert W. Baird Underperform
2020-06-18 Ripresa SunTrust Buy
2020-02-21 Iniziato Wells Fargo Equal Weight
2019-04-12 Iniziato Evercore ISI Outperform
2018-10-10 Iniziato Guggenheim Neutral
2018-09-21 Iniziato Raymond James Outperform
2018-05-15 Reiterato Chardan Capital Markets Buy
2018-02-13 Iniziato CLSA Underperform
2018-01-23 Aggiornamento SunTrust Hold → Buy
2017-07-14 Iniziato SunTrust Hold
2017-03-28 Iniziato Chardan Capital Markets Buy
2016-08-10 Aggiornamento Jefferies Hold → Buy
2016-06-02 Iniziato Jefferies Hold
2016-02-29 Iniziato JMP Securities Mkt Outperform
2016-02-29 Iniziato JP Morgan Neutral
2016-02-29 Iniziato Morgan Stanley Equal-Weight
Mostra tutto

Editas Medicine Inc Borsa (EDIT) Ultime notizie

pulisher
May 31, 2025

Millennium Management LLC Cuts Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World

May 31, 2025
pulisher
May 30, 2025

Two Sigma Advisers LP Grows Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 30, 2025
pulisher
May 30, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Purchased by BNP Paribas Financial Markets - Defense World

May 30, 2025
pulisher
May 30, 2025

Northern Trust Corp Has $884,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - Defense World

May 30, 2025
pulisher
May 28, 2025

Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat

May 28, 2025
pulisher
May 28, 2025

Editas Medicine (EDIT) Joins Russell Microcap Index - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com

May 28, 2025
pulisher
May 26, 2025

Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges By Investing.com - Investing.com Canada

May 26, 2025
pulisher
May 26, 2025

Editas Medicine’s SWOT analysis: gene editing stock pivots amid challenges - Investing.com Australia

May 26, 2025
pulisher
May 25, 2025

1 Stock Down 97% That Could Double, According to Wall Street - The Globe and Mail

May 25, 2025
pulisher
May 24, 2025

Tang Capital Management LLC Purchases Shares of 400,000 Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 24, 2025
pulisher
May 23, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Brokerages - Defense World

May 23, 2025
pulisher
May 22, 2025

Jacobs Levy Equity Management Inc. Has $900,000 Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 22, 2025
pulisher
May 21, 2025

Editas Medicine, Inc.'s (NASDAQ:EDIT) Price Is Right But Growth Is Lacking After Shares Rocket 28% - simplywall.st

May 21, 2025
pulisher
May 20, 2025

Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT S - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

May 19, 2025
pulisher
May 19, 2025

Editas Medicine (EDIT) Shifts Focus to In Vivo Programs | EDIT Stock News - GuruFocus

May 19, 2025
pulisher
May 18, 2025

Stifel Financial Corp Sells 287,718 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 18, 2025
pulisher
May 18, 2025

Robert W. Baird Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $4.00 - MarketBeat

May 18, 2025
pulisher
May 17, 2025

Balyasny Asset Management L.P. Grows Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 17, 2025
pulisher
May 16, 2025

Crispr Therapeutics Products 2025: Therapies, MOA Insights, - openPR.com

May 16, 2025
pulisher
May 16, 2025

Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by StockNews.com - Defense World

May 16, 2025
pulisher
May 15, 2025

Editas Medicine: A Cautionary Tale for Investors - AOL.com

May 15, 2025
pulisher
May 15, 2025

Raymond James Financial Inc. Invests $303,000 in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat

May 15, 2025
pulisher
May 15, 2025

A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory - Pharma Voice

May 15, 2025
pulisher
May 15, 2025

Robert W. Baird Issues Pessimistic Forecast for Editas Medicine (NASDAQ:EDIT) Stock Price - Defense World

May 15, 2025
pulisher
May 14, 2025

Editas Medicine Reports Q1 2025 Progress and Financials - TipRanks

May 14, 2025
pulisher
May 14, 2025

Editas Medicine: A Cautionary Tale For Investors - Barchart.com

May 14, 2025
pulisher
May 14, 2025

Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN

May 14, 2025
pulisher
May 14, 2025

Editas Medicine to Present in vivo HSC Delivery, Editing, and Bi - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Editas Medicine to Present in vivo HSC Delivery, Editing, - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the ... - Bluefield Daily Telegraph

May 14, 2025
pulisher
May 14, 2025

Editas optimistic on CRISPR patent outcome after appeal By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Editas Medicine (EDIT) Advances Gene Editing for Blood Disorders with Promising Results | EDIT Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports New In Vivo Data Highlighting The Potential Of Editas' Gene Upregulation Strategy In Hscs At The American Society Of Gene And Cell Therapy Annual Meeting - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports New In Vivo Data Highlighting the Potent - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs - TipRanks

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Unveils Promising Gene Editing Data - TipRanks

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports Promising In Vivo Gene Editing Results for Sickle Cell Disease and Beta Thalassemia at ASGCT Annual Meeting - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports New In Vivo Data Highlighting the - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - TradingView

May 14, 2025
pulisher
May 14, 2025

Editas Medicine at BofA Securities 2025: In Vivo Gene Editing Focus - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Dimensional Fund Advisors LP - Defense World

May 14, 2025
pulisher
May 14, 2025

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Wells Fargo & Company MN - MarketBeat

May 14, 2025
pulisher
May 14, 2025

Breakthrough: Editas Medicine's New Gene Therapy Data Shows 48% Success Rate for Sickle Cell Disease Treatment - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Editas Medicine Reports New In Vivo Proof of Concept Data - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Transcript : Editas Medicine, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com

May 13, 2025

Editas Medicine Inc Azioni (EDIT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):